Confirmed Control Closed Transaction verified ConsumerConsumer HealthConsumer Health / OTC PharmaceuticalsOTC MedicinesPharmaceutical Manufacturing

Viatris OTC business acquired by Cooper Consumer Health

Cooper Consumer Health acquired Viatris OTC business, an Europe consumer health / otc pharmaceuticals brand on Oct 1, 2023. The transaction value is shown as EUR 1.9bn.

Transaction summary

Target: Viatris OTC business
Acquirer: Cooper Consumer Health
Seller: Viatris
Announced: 2023-10-01
Geography: Europe
Tags: ConsumerConsumer HealthConsumer Health / OTC PharmaceuticalsOTC MedicinesPharmaceutical Manufacturing
Type: Acquisition
Deal type: Control
Stake acquired: -
First added: 2026-06-19
Latest update: 2026-07-12

Value and multiples

Price / value

EUR 1.9B

Consideration | EUR

Basis: Public source

Approx. $2.1B USD using FX date 2023-09-29 at 1.0594 EUR/USD.

EV / revenue

Period: Undisclosed

Basis: Public source

EV / EBITDA

EBITDA basis not stated

Basis: Public source

Basis

EUR 1.9bn consideration is treated as publicly disclosed or derived directly from public source data.
Metric period: Undisclosed.

Other reviewed estimates

Transaction comps can involve reported or estimated figures from different sources. FundComb uses the values above as the current canonical comp, while preserving prior reviewed estimates below for context.

Pasted spreadsheet lists EV/sales multiple of 3.6x and EBITDA multiple of 12.8x; supplied public web evidence verifies the transaction but not the multiples.

EV / revenue 3.6x | EV / EBITDA 12.8x

Source summary

Viatris Form 8-K — completion of Cooper Consumer Health OTC divestiture

Confirmed

Viatris disclosed up to EUR 1.95 billion cash consideration: EUR 1.85 billion at closing plus up to EUR 100 million contingent consideration.

Open source